Immunogen's stock value cut nearly in half after disappointing cancer trial
Shares of Immunogen Inc. IMGN, +2.61% plummeted 48% toward a two-year low in premarket trade Friday, after the company said a phase 3 trial of its ovarian cancer treatment, mirvetuximab soravtansine, compared to chemotherapy, failed to meet its primary endpoint of progression free survival.
Have breaking news sent to your inbox. Subscribe to MarketWatch's free Bulletin emails. Sign up here.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
UPDATE: Horizon Pharma stock soars 17% premarket on positive trial of eye disease treatment
Read more »
Cancer patient's treatment leaves radiation contamination in crematoryRadioactivity was detected on the oven, vacuum filter and bone crusher of an Arizona crematory where a deceased man who'd received radiation therapy was incinerated, according to a new case report. Worse still, a radioactive compound unrelated to the dead man was detected in the urine of an employee there.
Read more »
Nearly half of all tech executives say the blockchain revolution is coming, survey findsA surprising number of tech companies are hitching their cart to blockchain and expect major changes to their business as a result, within just a few years. That’s according to a recent survey conducted by Big Four accounting firm KPMG.
Read more »
Why Americans are on track to eat the most eggs in nearly a half-centuryThe resurgence of eggs follows updated government guidelines, trending diets, and a new understand of fats and cholesterol.
Read more »
Despite Their Priorities, Nearly Half Of Americans Over 55 Still Don't Have A WillThe major takeaway is that nearly half of those over 55 have not yet created a will. Despite that finding, there is a widely held belief that one should have their affairs in order by age 50. The obvious disconnect was particularly striking.
Read more »
Republican Party chair says primary challengers to Trump would 'lose horribly'“They have the right to jump in and lose, that’s fine,” Ronna McDaniel said at the Conservative Political Action Conference, an annual political gathering of Republicans near Washington. “They will lose horribly.” Former Ohio Governor John Kasich, who ran against Trump for the Republican nomination
Read more »
RNC chair says Trump primary challengers will 'lose horribly'"They have the right to jump in and lose, that's fine," McDaniel said while speaking at the Conservative Political Action Conference.
Read more »
McDaniel on Trump primary challengers: 'They will lose horribly'Republican National Committee Chairwoman Ronna McDaniel sardonically opened the door to potential GOP challengers to President Donald Trump in the 2020 election, but warned that 'they will lose horribly.'
Read more »